Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL906141 | 1.00 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL20319037 | 1.00 | CFTR (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL14786230 | 0.89 | L3MBTL1 (0.46) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL29669002 | 0.85 | SLC6A4 (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL3465672 | 0.85 | SLC6A4 (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL6855637 | 0.85 | SLC6A4 (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| SCHEMBL1037866 | 0.85 | SLC6A4 (0.48) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL9073846 | 0.83 | SLC6A4 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL29484721 | 0.83 | SLC6A4 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC | |
| Hydrochloric Acid SCHEMBL20302615 | 0.83 | SLC6A4 (0.47) | CFTRSLC6A2SLC6A4SLC6A3GOPC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732046-B2 | Substituted 1,2,4-triazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160031835-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. | 2016-02-04 | — | — | US | disclosed |
| EP-2346868-B1 | AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2016-01-27 | — | — | EP | disclosed |
| US-9139560-B2 | Substituted pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2015-09-22 | — | — | US | disclosed |
| EP-2277865-B1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2014-11-12 | — | — | EP | disclosed |
| US-20140221396-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD. (US) | 2014-08-07 | — | — | US | disclosed |
| US-20130274263-A1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY LTD | 2013-10-17 | — | — | US | disclosed |
| EP-1904478-B1 | ACID ADDITION SALTS OF N-ETHYL-N'-[2-METHOXY-4-(5-METHYL-4-{[(1S)-1-PYRIDIN-3-YLBUTYL]AMINO}PYRIMIDIN- 2-YL)PHENYL]UREA AND USES THEREOF | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2013-07-24 | — | — | EP | disclosed |
| US-8394806-B2 | 2-phenyl pyrazines as tubulin inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2013-03-12 | — | — | US | disclosed |
| US-8338610-B2 | Pyridinyl compounds useful as intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-31 | — | — | US | disclosed |
| US-20110269760-A1 | TUBULIN INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-11-03 | — | — | US | disclosed |
| US-7981900-B2 | Modulation microtubules diseases; antiproliferative agents; antiinflamamtory agents | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2011-07-19 | — | — | US | disclosed |
| EP-1689715-B1 | TUBULIN INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2011-02-09 | — | — | EP | disclosed |
| EP-2277865-A1 | Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors | YM BioSciences Australia Pty Ltd (AU) | 2011-01-26 | — | — | EP | disclosed |
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-15 | — | — | US | disclosed |
| US-20090281119-A1 | ACID ADDITION SALTS OF N-ETHYI-N'-[2-METHOXY-4-(5-METHYI-4-PRYIMIDIN-2-YL)PHENYL]UREA AND USES THEREOF | CYTOPIA RESEARCH PTY LTD. (AU) | 2009-11-12 | — | — | US | disclosed |
| US-20080194583-A1 | Tubulin Inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093724-A1 | Azaindazole Compounds As CCR1 Receptor Antagonists | CCR1, CCR3, CCR4 | CFTR 369/4885SLC6A2 4643/4885SLC6A4 4396/4885 |
| US-20160031835-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CFTR 3227/4885SLC6A2 3835/4885SLC6A4 4479/4885 |
| US-20080194583-A1 | Tubulin Inhibitors | TUBB1, TUBB3, TUBA1C | CFTR 3271/4885SLC6A2 3799/4885SLC6A4 4446/4885 |
| US-20090281119-A1 | ACID ADDITION SALTS OF N-ETHYI-N'-[2-METHOXY-4-(5-METHYI-4-PRYIMIDIN-2-YL)PHENYL]UREA AND USES THEREOF | PAH, CCNY, UMPS | CFTR 1608/4885SLC6A2 157/4885SLC6A4 83/4885 |
| US-20110269760-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CFTR 3227/4885SLC6A2 3835/4885SLC6A4 4479/4885 |
| US-20120136158-A1 | Pyridinyl Compounds Useful As Intermediates | CCR1, CCRL2, CCR4 | CFTR 541/4885SLC6A2 4677/4885SLC6A4 4328/4885 |
| US-20130274263-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CFTR 3227/4885SLC6A2 3835/4885SLC6A4 4479/4885 |
| US-20140221396-A1 | TUBULIN INHIBITORS | TUBB1, TUBB3, TUBA1C | CFTR 3227/4885SLC6A2 3835/4885SLC6A4 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.